Resumo

SIJO YERO, Anett et al. Efficacy and safety of erythropoietin for anemia of prematurity. Rev Cubana Pediatr [online]. 2013, vol.85, n.2, pp. 202-212. ISSN 0034-7531.

Introduction: recombinant alpha erythropoietin is part of the treatment for anemia of prematurity. The use of this one in Cuba has been restricted and controversial as to schedule and dose. Methods: prospective, non-randomized multicenter assay on the safety and efficacy of erythropoietin in the reduction of blood transfusion in very-low-weight preterm newborn. Seventy two neonates with gestational age under 34 post-menstruation weeks, weighing equal or less than 1 500 g, over 7 days of life after birth and fed on 50 mL/kg/day were included in the study. Results: all of them received 300 U/kg erythropoietin by subcutaneous administration three times a week up to reaching 40 weeks of gestational age and an iron and vitamin supplement. Erythropoietin is very safe; it was just possibly related to slight retinopathy of prematurity, but overcome. Conclusions: seven patients were transfused (9.7 %) in the course of study. The late use of erythropoietin in very-low-weight preterm child confirms its efficacy and safety.

Palavras-chave : anemia of prematurity; red blood cell transfusion; human recombinant erythropoietin; neonatal transfusion.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )